• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Elife . Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

tetano

Editor, Senior Moderator
Elife


. 2021 Jul 29;10:e69317.
doi: 10.7554/eLife.69317. Online ahead of print.
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains


Nikhil Faulkner[SUP] 1 [/SUP], Kevin W Ng[SUP] 1 [/SUP], Mary Y Wu[SUP] 2 [/SUP], Ruth Harvey[SUP] 3 [/SUP], Marios Margaritis[SUP] 4 [/SUP], Stavroula Paraskevopoulou[SUP] 4 [/SUP], Catherine Houlihan[SUP] 5 [/SUP], Saira Hussain[SUP] 6 [/SUP], Maria Greco[SUP] 6 [/SUP], William Bolland[SUP] 1 [/SUP], Scott Warchal[SUP] 2 [/SUP], Judith Heaney[SUP] 4 [/SUP], Hannah Rickman[SUP] 4 [/SUP], Moria Spyer[SUP] 4 [/SUP], Daniel Frampton[SUP] 4 [/SUP], Matthew Byott[SUP] 4 [/SUP], Tulio de Oliveira[SUP] 7 [/SUP], Alex Sigal[SUP] 8 [/SUP], Svend Kjaer[SUP] 9 [/SUP], Charles Swanton[SUP] 9 [/SUP], Sonia Gandhi[SUP] 10 [/SUP], Rupert Beale[SUP] 11 [/SUP], Steve J Gamblin[SUP] 11 [/SUP], John W McCauley[SUP] 12 [/SUP], Rodney Stuart Daniels[SUP] 3 [/SUP], Michael Howell[SUP] 13 [/SUP], David Bauer[SUP] 6 [/SUP], Eleni Nastouli[SUP] 4 [/SUP], SAFER Investigators; George Kassiotis[SUP] 1 [/SUP]



Affiliations

Abstract

Background: The degree of heterotypic immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging variants and the success of vaccination campaigns, but remains incompletely understood.
Methods: We examined the immunogenicity of SARS-CoV-2 variant B.1.1.7 (Alpha) that arose in the United Kingdom and spread globally. We determined titres of spike glycoprotein-binding antibodies and authentic virus neutralising antibodies induced by B.1.1.7 infection to infer homotypic and heterotypic immunity.
Results: Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa variant B.1.351 (Beta) than of the infecting variant. The drop in cross-reactivity was significantly more pronounced following B.1.1.7 than parental strain infection.
Conclusions: The results indicate that heterotypic immunity induced by SARS-CoV-2 variants is asymmetric.

Keywords: epidemiology; global health; human; infectious disease; microbiology; viruses.
 
Back
Top Bottom